Crystal Structure and Mutational Analysis of Heparan Sulfate 3-O-Sulfotransferase Isoform 1*

Received for publication, January 30, 2004, and in revised form, March 10, 2004 Published, JBC Papers in Press, April 1, 2004, DOI 10.1074/jbc.M401089200

Suzanne C. Edavettalı, Karen A. Lee, Masahiko Negishi, Robert J. Linhardt, Jian Liu, and Lars C. Pedersen

From the ‡Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599; §Laboratory of Structural Biology and Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709; and ¶Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, New York 12180

Heparan sulfate interacts with antithrombin, a protease inhibitor, to regulate blood coagulation. Heparan sulfate 3-O-sulfotransferase isoform 1 performs the crucial last step modification in the biosynthesis of anticoagulant heparan sulfate. This enzyme transfers the sulfuryl group (SO₃⁻) from 3′-phosphoadenosine 5′-phosphosulfate to the 3-OH position of a glucosamine residue to form the 3′-sulfoglucosamine, a structural motif critical for binding of heparan sulfate to antithrombin. In this study, we report the crystal structure of 3-O-sulfotransferase isoform 1 at 2.5 Å resolution in a binary complex with 3′-phosphoadenosine 5′-phosphate. This structure reveals residues critical for 3′-phosphoadenosine 5′-phosphosulfate binding and suggests residues required for the binding of heparan sulfate. In addition, site-directed mutagenesis analyses suggest that residues Arg-67, Lys-123, and Arg-276 are essential for enzymatic activity. Among these essential amino acid residues, we find that residues Arg-67, Arg-72, His-92, and Asp-95 are conserved in heparan sulfate 3-O-sulfotransferases but not in heparan N-deacetylase/N-sulfotransferase, suggesting a role for these residues in conferring substrate specificity. Results from this study provide information essential for understanding the biosynthesis of anticoagulant heparan sulfate and the general mechanism of action of heparan sulfate sulfotransferases.

Heparan sulfate (HS) is widely expressed in animal and human tissues. It has diverse roles in development, assisting viral infections, and homeostasis (1–3). HS is a highly sulfated polysaccharide consisting of 1–4-linked sulfated glucosamine and sulfated glucuronic/iduronic acid residues. The specific sequences of sulfated saccharide in HS determine its various functions.

Synthesis of biologically active HS is accomplished through a complex biosynthetic pathway. HS is initially synthesized as a copolymer of glucuronic acid and N-acetylated glucosamine by glucuronid and N-acetyl-D-glucosaminyltransferase followed by various modifications in the Golgi apparatus (4). These modifications include N-deacetylation and N-sulfonation of glucosamine, C₅ epimerization of glucuronic acid to form iduronic acid residues, and 2-O-sulfonation of iduronic and glucuronic acid residues as well as 6-O-sulfonation and 3-O-sulfonation of the glucosamine units. The stepwise sulfonation reactions are illustrated in Fig. 1. All of the enzymes that are responsible for the biosynthesis of HS have been cloned and characterized (5).

The blood coagulation pathway is composed of a cascade of proteolytic reactions ultimately generating fibrin thrombi. The proanticoagulant activity of this cascade is balanced by several natural anticoagulant mechanisms. Binding of HS to antithrombin (AT) represents the most important of these mechanisms. HS achieves its anticoagulant activity by interacting with AT, which undergoes a conformation change, generating the active form of AT to inhibit blood coagulation factors Xa and thrombin. This anticoagulant process prevents the formation of deleterious blood clots. Heparin, a specialized HS found in mast cells, is the most commonly used anticoagulant drug. Anticoagulant HS and heparin contain structurally defined AT binding pentasaccharide sequences with the structure, -GlcNS(or Ac)₆S-GlcUA-GlcNS₃S- (6). A recently approved anticoagulant drug, Arixtra, prepared by organic synthesis is based on this pentasaccharide scaffold. The recently reported enzymatic synthesis of a similar pentasaccharide utilizes 3-OST-1 in the last modification step (5) and opens up a new approach to preparation of such anticoagulants.

The essential physiological role of 3-O-sulfos HS (or anticoagulant HS) in blood coagulation is best demonstrated through the study of AT and AT mutants. A severe thrombosis phenotype is observed in mice carrying an AT mutant defective in heparin binding, suggesting a key role for HS-AT interaction in balancing procoagulant and anticoagulant activities in vivo (7). Additionally, patients with AT mutants defective in heparin and HS binding suffer from thrombosis (8–10). Furthermore, it appears that complete ablation of AT-HS binding is required to...
reveal the full physiological role of anticoagulant HS \textit{in vivo} (11). The final step in the biosynthesis of anticoagulant HS can be catalyzed by either 3-OST-1 or 3-OST-5 isoforms (12, 13). Gene redundancy in the biosynthesis of anticoagulant HS helps to explain why 3-OST-1 knockout mice failed to exhibit a pro-thrombotic phenotype (14).

Heparan sulfate 3-O-sulfotransferase (3-OST) is present in at least six different isoforms that have unique expression patterns in human tissues (15, 16). The amino acid sequences of the different isoforms have 50–80% homology in their sulfotransferase domains (15). These different 3-OST isoforms transfer sulfuryl groups to the 3-OH position of glucosamine units residing within the context of different saccharide sequences. As a result, the HS products generated by these different isoforms exhibit unique and distinctive biological activities. It is known that HS modified by 3-OST-1 and 3-OST-5 display anticoagulant activity, whereas HS modified by 3-OST-3 and 3-OST-5 serve as entry receptors for herpes simplex virus-1 (12, 16, 17). The structural features of 3-OST isoforms that dictate substrate specificity are currently unknown.

The sulfotransferase family can be organized into two categories based on the sub-cellular localizations; they are cytosolic and Golgi sulfotransferases (18, 19). The crystal structures of different sulfotransferases reveal structural similarity in their PAPS binding sites between the cytosolic and Golgi sulfotransferases, suggesting that different sulfotransferases probably follow similar mechanisms in the transfer of the sulfuryl group even though they exhibit high selectivity in substrate binding (20, 21). The structures of a number of cytosolic sulfotransferases complexed with acceptor substrates have been solved, providing clues that have led to a better understanding of their catalytic mechanism and mode of substrate recognition (22–24). HS sulfotransferases are considered to be Golgi sulfotransferases. The crystal structure of the binary complex of the sulfotransferase domain of the HS \(N\)-deacetylase/N-sulfotransferase (NST-1) and 3'-phosphoadenosine 5'-phosphate (PAP) was solved by Kakuta et al. (21). This represents the first and only structure of a HS sulfotransferase previously determined.

In this study, we report the crystal structure of a binary complex of mouse 3-OST-1 and PAP. The structure of this enzyme is very similar to NST-1 but with unique structural features in the HS binding cleft. Results from mutational analysis of amino acid residues at and around the active site in
Crystal Structure of 3-OST-1

Table I

Crystalllographic data statistics

| Data set          | 3-OST-1 (high) | 3-OST-1 (low) |
|-------------------|----------------|---------------|
| Unit cell         | a = b = 200.14 c = 84.20 | a = b = 288.69 c = 83.82 |
| Space group       | 14 (1) 22      | 14 (1) 22     |
| No. of observations | 741,873        | 180,101       |
| Unique reflections | 63,928         | 42,945        |
| R<sub>cryst</sub> (%)(last shell) | 11.6 (37.1) | 13.7 (61.5) |
| I/σ(I) (last shell) | 7.4 (1.7)    | 6.7 (1.4)     |
| Mosaicity         | 0.41           | 0.62          |
| Completeness (%)  | 96.7 (83.6)    | 93.9 (82.4)   |
| Refinement statistics |               |               |
| Resolution (Å)    | 25.0–2.5       | 25.0–2.8      |
| R<sub>cryst</sub> (%)<sup>a</sup> | 24.3          |               |
| R<sub>free</sub>  (%)<sup>b</sup> | 26.4          |               |
| No. of water      | 178            |               |
| Mean B value (Å)  | 58.3           |               |
| For:              | Complex A      | Complex B     | Complex C     |
| Protein           | 43.06          | 39.17         | 100.69        |
| PAP               | 31.23          | 33.18         | 69.76         |

<sup>a</sup> R<sub>cryst</sub> = \(\sum I / \{I - (1/|\bar{I}|)I\bar{I}\} / \sum I\) where I<sub>i</sub> is the intensity of the i<sub>b</sub> observation, and \(I\) is the mean intensity of the reflection.

<sup>b</sup> R<sub>free</sub> = \(\sum F - |F| / \sum F\) calculated from working data set.

<sup>c</sup> R<sub>free</sub> was calculated from 5% of data randomly chosen not to be included in refinement.

<sup>d</sup> Ramachandran results were determined by MolProbity.

**EXPERIMENTAL PROCEDURES**

**Materials**—Full-length mouse 3-OST-1 cDNA (m3-OST-1-pcDNA3) was purified from a mouse L-cell cDNA library (25). [35S]PAPS was prepared by incubating 0.4–2 mCi/ml [35S]Na<sub>2</sub>SO<sub>4</sub> (carrier-free, MP Biomedical<sup>e</sup>) and 16 m M ATP with 5 mg/ml dialyzed yeast extract (Sigma) (26). HS from bovine kidney was purchased from MP Biomedical (Irving, CA). PAP was purchased from Sigma.

**Expression, Purification, and Crystallization of 3-OST-1**

Preparation of 3-OST-1 Bacterial Expression Plasmid (b3-OST-1-pET28)—The cDNA fragment encoding the catalytic domain of 3-OST-1 (G48-H311) was amplified from m3-OST-1-pcDNA3 with a 5′ overhang containing an NdeI site and a 3′ overhang containing an EcoRI site. This construct was inserted into the pET28a vector (Novagen) using the NdeI and EcoRI restriction sites to produce a His<sub>r</sub>-tagged protein. The resultant plasmid (b3-OST-1-pET28) was sequenced to confirm the reading frame and the lack of mutations within the coding region (University of North Carolina, DNA sequencing core facility). The plasmid, b3-OST-1-pET28, was transformed into BL21(DE3)RIL cells (Stratagene) for the expression of 3-OST-1.

Protein Expression and Purification—Cells containing the b3-OST-1-pET28 were grown in 12 2.8-liter Fernbach flasks containing 1 liter of LB media with 50 µg/ml kanamycin at 37°C. When the A<sub>600</sub> reached 0.6–0.8, the temperature was lowered to 22°C for 15 min. Isopropyl-β-D-thiogalactopyranoside was then added to a final concentration of 200 µM, and the cells were allowed to shake overnight. Cells were pelleted and resuspended in 120 ml of sonication buffer, 25 mM Tris, pH 7.5, 500 mM NaCl, and 10 mM imidazole. Cells were disrupted by sonication then spun down. The supernatant was applied to nickel nitrilotriacetic acid-agarose resin (Qiagen) in batch and washed with sonication buffer. The resin was eluted with an imidazole gradient from 10 to 250 mM. The protein was dialyzed then concentrated to 16 mg/ml in 20 mM Tris, pH 7.5, 100 mM NaCl, and 4 mM PAP. A total of 28 mg of protein was obtained.

Protein Crystallization and Structure Solution—Crystals of 3-OST-1 were grown using the hanging drop method at 4°C by mixing 2 µl of the protein solution with 2 µl of the reservoir solution containing 0.1 M citrate, pH 5.5, and 11% polyethylene glycol 4000. Before data collection, crystals were transferred to a solution containing 0.1 mM citrate, pH 5.5, 20% polyethylene glycol 4000, 0.1 mM NaCl, 4 mM PAP, and 12.5% ethylene glycol. The crystals were mounted in a loop and flash-frozen in liquid nitrogen. Data were collected at −180°C on a Raxis IV area detector for the low resolution data set. A high resolution data set was collected on another crystal at the Advanced Photon Source on SER-CAT beamline 22 using a MAR225 area detector. Both data sets were processed using HKL2000 (Table I) (27). A model of NST-1 (21) consisting of residues 603–632, 642–684, 670–736, 744–768, and PAP was used as a search molecule for molecular replacement using Molrep in CCP4 with the low resolution data set (28, 29). The positions of two (A and B) of the three final molecules in the asymmetric unit were found by molecular replacement. These two molecules were refined in CNS (30) and improved by iterative cycles of model building in O (31) and refinement in CNS until an R<sub>f</sub> value of 35% was obtained. At this point, sparse electron density became visible for the third molecule (C). A copy of molecule A was manually inserted into the density and refined. Density for molecule C was very poor, and the B-factors were very high, so refinement was carried out using non-crystallographic restraints between the third molecule and the first molecule. Residues for molecule C, which contained no electron density, were deleted. The refinement of molecule C dropped the R<sub>f</sub> to 31%. The final model was obtained by iterative cycles of model building and refinement of the three molecules against the high resolution data set. The final molecule contains residues 54–311 for molecule A and B and 54–269 and 281–311 for molecule C.

Mutational Analysis of 3-OST-1

Preparation of 3-OST-1 Mutant Plasmids—A total of 28 point mutants of 3-OST-1 were prepared using b3-OST-1-pET28 as the template and the Gene Tailor site-directed mutagenesis kit from Invitrogen. The length and sequences of the primers for preparation of these mutants were designed based on the manufacturer’s protocol for this mutagenesis kit and were synthesized by Invitrogen. The resultant constructs were sequenced to confirm the anticipated mutation (University of North Carolina, DNA sequencing core facility).

Expression and Purification of 3-OST-1 Mutants—The expression plasmids for various 3-OST-1 mutants were transformed individually into BL21(DE3)RIL cells (Stratagene). Each mutant construct was grown in 100 ml of LB broth and induced by isopropyl-β-D-thiogalacto-
FIG. 2. The crystal structure of 3-OST-1 in complex with PAP. a, stereo ribbon diagram of the crystal structure of 3-OST-1. Also pictured is the donor product PAP and conserved residues Ser-159 and Lys-68 that interact with the 3'- and 5'-phosphates of PAP, respectively, as well as residue Glu-90, which has been proposed to be involved in catalysis. b, stereo diagram of the PAPS binding site of 3-OST-1 with PAP bound. The electron density for PAP from a simulated annealing omit map is drawn contoured at 8 \( \sigma \). Superimposed onto the active site are PAPS (pink) from the crystal structure of human estrogen sulfotransferase (PDB code 1HY3) and 17\( \beta \)-estradiol, the acceptor substrate, and the catalytic base His-108 (purple) from mouse estrogen sulfotransferase (PDB code 1AUQ). Superpositions are based on the PSB loop of these structures. These superpositions suggest the position of the sulfuryl group of PAPS in 3-OST-1 binding as well as the position of the acceptor hydroxyl of the heparan substrate (the 3-hydroxylation 17\( \beta \)-estradiol). Hydrogen bonds between 3-OST-1 and PAP are drawn in dashed black lines as well as the interaction between His-108 and 17\( \beta \)-estradiol in mouse estrogen sulfotransferase. Potential hydrogen bonds between 3-OST-1 residues and the sulfuryl group of PAPS are shown in dashed orange lines as is the potential interaction between Glu-90 and the acceptor hydroxyl of the substrate. The solid orange line (labeled with an asterisk) displays the direction of attack of the acceptor hydroxyl on the sulfuryl group for the proposed in-line transfer reaction mechanism. For this figure the oxygen, nitrogen, and phosphorous atoms are colored red, blue, and magenta, respectively. This figure was created using Molscript (37) and Raster3D (38).

pyranoside as described above. The bacteria cells were harvested and solubilized in sonication buffer before sonication. The lysate was subjected to a 400-\( \mu \)l nickel nitritolactiacte acid-agarose column (0.75 \( \times \) 1 cm) followed by a 5-ml of wash with sonication buffer. Mutant proteins were eluted with 1 ml of elution buffer containing 25 mM Tris, 500 mM NaCl, and 250 mM imidazole, pH 7.5. Approximately 25 \( \mu \)l of the eluent was subjected to the analysis on a 16.5% Tris-Tricine PAGE gel (Bio-Rad), and the gel was stained by Coomassie Blue. The expression level of the mutant protein was estimated by determining the intensity of the Coomassie-stained protein band near 30 kDa. As a positive control, we purified the \( [35S] \)HS. The quantity of \( [35S] \)HS was then determined by liquid scintillation counting. The negative control contained all the components with the exception of 3-OST-1 proteins.

**Determination of the Binding of AT and 3-O-Sulfated HS**—Approximately 5 \( \times \) 10\( ^5 \) cpm of \( [35S] \)HS was incubated with 5 \( \mu \)g of human AT (Cutter Biological) in 50 \( \mu \)l of reaction buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn\( ^{2+} \), 1 mM Mg\( ^{2+} \), 1 mM Ca\( ^{2+} \), 10 \( \mu \)M dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100 for 30 min at room temperature. 60 \( \mu \)l of 1:1 slurry of pretreated concanavalin A-Sepharose (from Sigma) was added, and the reaction was agitated for 1 h at room temperature on an orbital shaker. The gel was washed three times with the buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn\( ^{2+} \), 1 mM Mg\( ^{2+} \), 1 mM Ca\( ^{2+} \), 10 \( \mu \)M dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100, and the bound \( [35S] \)HS was eluted with the same buffer containing 1000 mM NaCl.

**ITC—ITC** was performed on a MicroCal VP-ITC. Solutions were cooled to 10°C and degassed under vacuum before use. Experiments were conducted using 17–21 \( \mu \)l protein in 100 mM phosphate buffer, pH 7.0, and 100 mM NaCl at 10°C. Determinations were performed by injecting 5 \( \mu \)l of 4 mM PAP in 100 mM phosphate buffer, pH 7.0, and 100 mM NaCl. Data analysis was completed using Origin software.

**Determination of PAP Binding Affinity Using PAP Chromatography**—To determine the binding affinity of the wild type and mutant proteins to PAP, 3',5'-ADP-agarose chromatography (Sigma) was used. Approximately 200 \( \mu \)g of proteins, including wild type 3-OST-1, K68A, H92F, and D95N and R276A, were grown in 2–4-liter cultures to –1% Triton X-100. The reaction was incubated at 37°C for 30 min and quenched by the addition of 6 mM urea and 100 mM EDTA. The sample was then subjected to a 200-\( \mu \)l DEAE-Sepharose chromatography to purify the \( [35S] \)HS. The quantity of \( [35S] \)HS was then determined by liquid scintillation counting. The negative control contained all the components with the exception of 3-OST-1 proteins.

**Determination of the Binding of AT and 3-O-Sulfated HS**—Approximately 5 \( \times \) 10\( ^5 \) cpm of \( [35S] \)HS was incubated with 5 \( \mu \)g of human AT (Cutter Biological) in 50 \( \mu \)l of reaction buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn\( ^{2+} \), 1 mM Mg\( ^{2+} \), 1 mM Ca\( ^{2+} \), 10 \( \mu \)M dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100 for 30 min at room temperature. 60 \( \mu \)l of 1:1 slurry of pretreated concanavalin A-Sepharose (from Sigma) was added, and the reaction was agitated for 1 h at room temperature on an orbital shaker. The gel was washed three times with the buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn\( ^{2+} \), 1 mM Mg\( ^{2+} \), 1 mM Ca\( ^{2+} \), 10 \( \mu \)M dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100, and the bound \( [35S] \)HS was eluted with the same buffer containing 1000 mM NaCl.

**ITC**—ITC was performed on a MicroCal VP-ITC. Solutions were cooled to 10°C and degassed under vacuum before use. Experiments were conducted using 17–21 \( \mu \)l protein in 100 mM phosphate buffer, pH 7.0, and 100 mM NaCl at 10°C. Determinations were performed by injecting 5 \( \mu \)l of 4 mM PAP in 100 mM phosphate buffer, pH 7.0, and 100 mM NaCl. Data analysis was completed using Origin software.

**Determination of PAP Binding Affinity Using PAP Chromatography**—To determine the binding affinity of the wild type and mutant proteins to PAP, 3',5'-ADP-agarose chromatography (Sigma) was used. Approximately 200 \( \mu \)g of proteins, including wild type 3-OST-1, K68A, H92F, and D95N and R276A, were grown in 2–4-liter cultures to –1% Triton X-100. The reaction was incubated at 37°C for 30 min and quenched by the addition of 6 mM urea and 100 mM EDTA. The sample was then subjected to a 200-\( \mu \)l DEAE-Sepharose chromatography to purify the \( [35S] \)HS. The quantity of \( [35S] \)HS was then determined by liquid scintillation counting. The negative control contained all the components with the exception of 3-OST-1 proteins.

**Determination of the Binding of AT and 3-O-Sulfated HS**—Approximately 5 \( \times \) 10\( ^5 \) cpm of \( [35S] \)HS was incubated with 5 \( \mu \)g of human AT (Cutter Biological) in 50 \( \mu \)l of reaction buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn\( ^{2+} \), 1 mM Mg\( ^{2+} \), 1 mM Ca\( ^{2+} \), 10 \( \mu \)M dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100 for 30 min at room temperature. 60 \( \mu \)l of 1:1 slurry of pretreated concanavalin A-Sepharose (from Sigma) was added, and the reaction was agitated for 1 h at room temperature on an orbital shaker. The gel was washed three times with the buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn\( ^{2+} \), 1 mM Mg\( ^{2+} \), 1 mM Ca\( ^{2+} \), 10 \( \mu \)M dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100, and the bound \( [35S] \)HS was eluted with the same buffer containing 1000 mM NaCl.
washing with 5 ml of 25 mM Tris, pH 7.0, and 100 mM NaCl. Bound proteins were eluted with a linear gradient of NaCl from 100 mM to 1 M in 10 ml. The samples from the collected fractions were analyzed by SDS-PAGE followed by staining with Coomassie Blue.

RESULTS AND DISCUSSION

Overall Fold—The catalytic domain of mouse 3-OST-1 (G48-H311) was successfully expressed in Escherichia coli. The catalytic domain has higher solubility than the full-length protein, making it more amenable to crystallization. The 3-OST-1 protein crystallized in the space group I4122 with 3 protein molecules (A, B, and C) in the asymmetric unit. Each molecule of 3-OST-1 contains one molecule of PAP bound. Two of the protein molecules (A and B) in the asymmetric unit stack together, forming hollow channels with the long dimension running parallel to the c axis of the unit cell. The rim of the channel is composed of 4 molecules of both A and B. The hollow inner solvent channel has a diameter of ~62 Å. The third molecule (C) is involved in cross-linking these channels by interacting with molecules B and a molecule C coming from another channel. This packing arrangement creates a cell with an overall solvent content of 76% and a Matthews coefficient of 5.5 (32). Molecules A and B are well ordered and have similar overall B-factors (Table I). Molecule C, however, is highly disordered, with overall B-factors ~2.5 times greater than molecules A and B, suggesting it may bind in slightly different orientations or have only partial occupancy in the crystal lattice. Because molecule C is highly disordered, the discussion of the structure will focus on molecules A and B.

The crystal structure of the 3-OST-1-PAP complex (Fig. 2a) is roughly spherical and contains a large open cleft. The structure is centered around a αβ motif common to all sulfotransferases (18). This motif consists of a five-stranded parallel β-sheet flanked on both sides by α helices. At the heart of the fold is a strand-loop-helix motif (Thr-61–Ser-79) consisting of the first β-strand (The-61–Ile-64) and the first α-helix (Thr-71–Ser-79), which contains the phosphosulfate binding (PSB) loop (Gly-65–Gly-70) (22). This loop is very similar in structure to the P-loop found in protein kinases and forms extensive interactions with the 5'-phosphate of the PAP (Fig. 2b). In addition to sulfotransferases, the helix that runs across the top of the PAP binding pocket and into the open cleft is also present. The C-terminal portion of the enzyme consists of a short three-
stranded anti-parallel β-sheet. Strands 2 and 3 of this sheet are stabilized by a disulfide bond (Cys-260–Cys-269). A coil consisting of residues 270–281 connects this sheet to the C-terminal helix. This coil practically buries the PAP molecule in the active site and may be susceptible to a conformational change since it is ordered in molecules A and B and there is no electron density visible for it in molecule C.

The overall fold of 3-OST-1 is most similar to that of the sulfotransferase domain of NST-1 (21) (Fig. 3a). The root mean square of 230 structurally equivalent Cαs is 1.3 Å, as determined by the program O (31). All of the significant secondary structural features are conserved between the two enzymes. The major differences occur in the loop regions as described below.

PAP Binding Site—A number of hydrogen-bonding interactions are involved in positioning the PAP molecule within the active site (Fig. 2b). Side chains from residues Lys-68 and Thr-71 of the PSB loop and Lys-274 of the coil that buries the PAP both form interactions with the 5′-phosphate (Table II). In addition, backbone amide nitrogens from the PSB loop (Gly-70, Thr-71, and Arg-72) are also within hydrogen-bonding distance of the 5′-phosphate. Although there are no protein interactions with the ribose ring, atom N6 of the adenosine base is within hydrogen-bonding distance to the carbonyl oxygen of Tyr-259. In addition, residues Phe-258, Ile-225, Ala-73, and Leu-270 are all within 4 Å of the base and assist in positioning the base through van der Waals forces.

Like the 5′-phosphate binding site, the 3′-phosphate also forms a number of interactions with the protein. The side chain of Arg-151 is within hydrogen-bonding distance to the bridging O3 oxygen. In addition, the side chain oxygen of Ser-159 also lies within hydrogen-bonding distance of Arg-151 as well as...
The wild type m3-OST-1 was constructed by replacing N-terminal 47 amino acid residues with a His<sub>6</sub> tag to facilitate the protein purification. Table III summarizes the analysis of 3-OST-1 mutants.

| Name of the constructs<sup>a</sup> | Expression level<sup>b</sup> | Relative activity<sup>c</sup> |
|----------------------------------|-----------------------------|-----------------------------|
| 3-OST-1 wild type                | +                           | 100.0                       |
| 3-OST-1 R67E                     | +                           | 1.1                         |
| 3-OST-1 R67A                     | +                           | 1.2                         |
| 3-OST-1 K65A                     | +                           | 0.1                         |
| 3-OST-1 R72A                     | +                           | 7.0                         |
| 3-OST-1 R72E                     | +                            | 0.0                         |
| 3-OST-1 E76A                     | +                            | 30.7                        |
| 3-OST-1 E76Q                     | +                            | 15.6                        |
| 3-OST-1 E58A                     | +                            | 63.7                        |
| 3-OST-1 N89A                     | +                            | 69.5                        |
| 3-OST-1 N89D                     | +                            | 74.4                        |
| 3-OST-1 E90Q                     | +                            | <0.0                        |
| 3-OST-1 E90A                     | +                            | 0.0                         |
| 3-OST-1 H92F                     | +                            | <0.0                        |
| 3-OST-1 H92A                     | +                            | 0.0                         |
| 3-OST-1 D95A                     | Somewhat lower than WT, detectable | <0.0 |
| 3-OST-1 D95N                     | Somewhat lower than WT, detectable | 8.1 |
| 3-OST-1 W96A                     | +                            | 91.6                        |
| 3-OST-1 W96P                     | +                            | 69.1                        |
| 3-OST-1 E98A                     | +                            | 65.6                        |
| 3-OST-1 K123A                    | +                            | 0.2                         |
| 3-OST-1 K132A                    | +                            | 49.1                        |
| 3-OST-1 R197A                    | +                            | 95.0                        |
| 3-OST-1 Q163A                    | +                            | 34.0                        |
| 3-OST-1 H271A                    | +                            | 109.0                       |
| 3-OST-1 H271F                    | +                            | 42.0                        |
| 3-OST-1 S273A                    | +                            | 99.6                        |
| 3-OST-1 K274A                    | +                            | 17.4                        |
| 3-OST-1 R276A                    | +                            | 0.3                         |

<sup>a</sup> The mutants were prepared using site-directed mutagenesis kit from Invitrogen. The constructs were sequenced to confirm the point mutations. The proteins were expressed in E. coli and purified by a nickel nitritrotriacetic acid-agarose column.

<sup>b</sup> The activity of 3-OST-1 was determined by following a method described in a prior publication (39), and 100% activity represents the transfer of 14 pmol of sulfate/μg of protein under the standard assay conditions.

<sup>c</sup> with a 3'-phosphate oxygen. Backbone amides from residues Gly-275 and Arg-276 of the flexible loop also form interactions with the phosphate. In molecule B, atom NE2 of the side chain from His-278 is within hydrogen-bonding distance of the phosphate as well; however, this residue has a different conformation in molecule A and consequently is not near the phosphate.

Catalytic Mechanism—Heparan sulfotransferases, including 3-OST-1 and NST-1, and cytosolic sulfotransferases recognize substrates that have distinct chemical structures. Based on structural similarities and utilization of the same sulfuryl donor, PAPS, it is believed that heparan sulfotransferases and cytosolic sulfotransferases share a common mechanism (33). Superposition of 3-OST-1 with structures of estrogen sulfotransferase, a representative cytosolic sulfotransferase, with PAPS and 17β-estradiol bound depicts the catalytic functions of the key amino acid residues for the activities of 3-OST-1 and estrogen sulfotransferase (Fig. 2b). The mechanism of the cytosolic sulfotransferases has been suggested to proceed through an S<sub>2</sub>2-like in-line displacement mechanism whereby the acceptor hydroxyl acts as a nucleophile, which when deprotonated by a conserved histidine attacks the sulfur atom of PAPS (20, 22). This creates a trigonal bi-pyramidal transition state with the PAP and acceptor group in the axial positions. The negative charge build up on the leaving PAP group is stabilized by a conserved lysine residue on the PSB loop that forms a hydrogen bond with the bridging oxygen to the sulfur atom. This lysine is in a similar conformation in both the structures of estrogen sulfotransferase in complex with PAP and 17β-estradiol and 3-OST-1 in complex with PAP. Interestingly, in the estrogen sulfotransferase-PAPS binary complex, the lysine lies in a different conformation and forms a hydrogen bond with a conserved serine that also forms hydrogen bonds with the 3'-phosphate of PAP (24). This interaction may be essential for all sulfotransferases to reduce the rate of hydrolysis of PAPS in the absence of acceptor substrate.

The lysine and serine residues, which are used by estrogen sulfotransferase to position and stabilize PAPS, are conserved in NST-1 (Lys-614, Ser-712) as well as in the 3-OSTs including 3-OST-1 (Lys-68, Ser-159, respectively) (Fig. 2b). The catalytic base, however, is not conserved between the estrogen sulfotransferase and the heparan sulfotransferases. The heparan sulfotransferases do not contain a residue structurally equivalent to the catalytic histidine found in cytosolic sulfotransferases such as the estrogen sulfotransferases. However, a conserved glutamate is located at a different position in the catalytic sites of NST-1 (Glu-642) and 3-OST-1 (Glu-90) (Fig. 2b). This glutamate residue was proposed to serve as the catalytic base for the activity of NST-1 (33, 34). In both 3-OST-1 and NST-1 structures, this glutamate is found on the inside of the large cleft. Mutation at Glu-90 of 3-OST-1 results in complete loss of sulfotransferase activity as described below, suggesting that Glu-90 is critical for the catalytic function of 3-OST-1.

Heparan Sulfate Binding Site—The large open cleft of the 3-OST-1 structure is believed to be the HS binding site (Fig 3a). This hypothesis is based on the fact that this open cleft in NST-1 has been shown to accommodate a hexasaccharide and provides access to the sulfonyl group of PAPS, where the sulfotransferase reaction occurs (34). Despite the overall fold of these two enzymes being similar, the cleft of 3-OST-1 differs from that of NST-1 in both the primary amino acid sequence and the distribution of the positively charged amino acid residues. NST-1 contains an insertion immediately before the catalytic base (residues Asn-633—Glu-641) that does not exist in 3-OST-1 (Fig. 3b and 4). Mutations from this loop F640A and E641A have a significant effect on NST-1 activity (34). Because these residues are not conserved in the 3-OSTs, it is unlikely that this loop of NST-1 plays a fundamental role in catalysis of all HS sulfotransferase reaction. Therefore, it is possible that this NST-1-specific loop helps the enzyme to recognize NST-1-specific saccharide units within its polysaccharide substrate (the structures of NST-1 and 3-OST-1 substrates are shown in Fig. 1).

The majority of the residues that line this cleft are not conserved. An increase in overall positive charge of the surface of the 3-OST-1 cleft as compared with the NST-1 cleft (Fig. 5) is consistent with the greater number of sulfo groups on the 3-OST-1 substrate than found on the NST-1 substrate (Fig. 1). Interestingly, additional electron density was found in the electron density maps of 3-OST-1 that we have modeled as inorganic sulfate. Residues Arg-72, Lys-123, and Lys-274 are all within hydrogen-bonding distance to the modeled inorganic sulfate (Table II). The position of this modeled inorganic sulfate may represent a sulfo group binding site for the HS substrate, confirming the hypothesis that this is the HS substrate binding site. The catalytic base, however, is not conserved between the estrogen sulfotransferase and the heparan sulfotransferases. The heparan sulfotransferases do not contain a residue structurally equivalent to the catalytic histidine found in cytosolic sulfotransferases such as the estrogen sulfotransferases. However, a conserved glutamate is located at a different position in the catalytic sites of NST-1 (Glu-642) and 3-OST-1 (Glu-90) (Fig. 2b). This glutamate residue was proposed to serve as the catalytic base for the activity of NST-1 (33, 34). In both 3-OST-1 and NST-1 structures, this glutamate is found on the inside of the large cleft. Mutation at Glu-90 of 3-OST-1 results in complete loss of sulfotransferase activity as described below, suggesting that Glu-90 is critical for the catalytic function of 3-OST-1.
and around the PAPS binding site and the proposed HS binding cleft were mutated. The results of the mutagenesis study are summarized in Table III. The positions of the mutation sites at the active site of 3-OST-1 are shown in Fig. 6. Binding of enzymatically modified HS to AT were compared in those mutants that retained sulfotransferase activity. HS modified by all of these mutants bound to AT, suggesting that these mutant proteins maintain the substrate specificity of 3-OST-1. These results suggest that the PAP binding affinities of mutant K68A are consistent with our crystal structure data that reveals the side chain of Lys-68 is in position to form a hydrogen bond with the 5'-phosphate of PAP.

To decipher the specific roles of these individual amino acids in catalysis, binding affinity for PAP was measured and compared with wild type using ITC analysis (Table IV). The use of PAP as an analog for mimicking the interaction between PAPS and sulfotransferases is a widely used approach, provided that the binding affinity of sulfotransferases to PAP is similar to the affinity of sulfotransferase to PAPS (18). Indeed, we determined the $K_D$ of 3-OST-1 (WT) for PAP to be 14 µM, very close to the $K_M$ of wild type 3-OST-1 for PAPS, determined by kinetic analysis (35). Our result suggests that the PAP binding affinity of 3-OST-1 provides a good estimate for the binding affinity to PAPS. The binding affinity ($K_D$ values) of the protein to PAP among the mutants K123A, R67E, E90Q, and R72E is similar to the wild type protein, suggesting that residues Arg-67, Arg-72, Glu-90, and Lys-123 are not directly involved in the binding to PAP. However, we were unable to accurately determine the $K_D$ values for mutants K68A and mutant R276A because the binding affinity is too low. We next compared the binding/elution profiles of these proteins on a PAP-agarose column. We find that the wild type 3-OST-1 protein was eluted from the column at 1 mM NaCl, whereas 3-OST-1 K68A and 3-OST-1 R276A were eluted at 600 and 150 mM NaCl, respectively (chromatograms not shown). These results suggest that the PAP binding affinities of 3-OST-1 K68A and 3-OST-1 R276A are indeed significantly reduced. The decrease in the PAP binding affinity of mutant K68A is consistent with our crystal structure data that reveals the side chain of Lys-68 is in position to form a hydrogen bond with the 5'-phosphate of PAP. However, the reason for a decrease in the PAP binding affinity of mutant R276A is unclear since the side chain of this arginine residue points away from both the 3'-phosphate and 5'-phosphate of PAP.

Among those mutants that have a significant decrease in activity, Glu-90 and Lys-123 of 3-OST-1 are conserved in NST-1 (Glu-642 and Lys-676, respectively) and other 3-OSTs, suggesting that these two residues serve similar functions for the activities of these HS sulfotransferases. As described above, the proposed function of Glu-90 of NST-1 or Glu-642 of NST-1 is to serve as a catalytic base in an SN2-like in-line displacement reaction. Indeed, mutations in Glu-642 of NST-1 and Glu-90 of 3-OST-1 abolished sulfotransferase activity (34). The crystal structure data suggest that Lys-123 in 3-OST-1 is in a position to interact with the sulfo group of PAPS (Fig. 2b). This interaction has also been suggested to occur in NST-1 (Lys-676) based on modeling of PAPS into the active site (33). It is possible that the role of Lys-123 is not to increase binding affinity for PAPS but rather to assist in stabilizing the transition state by interacting with the equatorial oxygen atoms of the sulfo group.

Several amino acid residues critical for the sulfotransferase activity of 3-OST-1 are conserved in other 3-OST isoforms, including 3-OST-1, -2, -3, -4, and -5, but are not conserved in NSTs (36) (Fig. 4). These residues include Arg-67, Arg-72,
His-92, and Asp-95. This observation suggests that these residues contribute to the substrate specificity of 3-O-sulfotransferases. At the present time, it is unclear how these amino acid residues contribute to the substrate specificity, namely how 3-OST sulfonates the 3-OH position, whereas NST sulfonates the 2-amino position of the glucosamine unit. In addition, a possible catalytic role for residues His-92 and Asp-95 cannot be ruled out. Atom NE2 of His-92 from 3-OST-1 is only 3.3 Å away from a carboxylate oxygen atom of the proposed base Glu-90. Additionally, Asp-95 forms a hydrogen bond with ND1 of His-92. This sequence of residues (Glu-90–His-92–Asp-95) provides for a potential hydrogen-bonding network. Supporting this hypothesis, the mutant D95N, which could geometrically maintain the hydrogen-bonding network, does retain some sulfotransferase activity, whereas the D95A mutant does not (Table III). Interestingly in NST-1, Gln-644 is within hydrogen-bonding distance of Glu-642 (3.1 Å) the proposed base. The positive charge on these arginine residues in 3-OST-1 may assist in the interaction of these residues with negatively charged sulfoglycopeptide. From the present study we are unable to reveal the precise molecular details of the substrate specificity differences between the 3-OSTs. Although the present study does not reveal the mechanism of substrate specificity differences between the 3-OSTs, the results from this study provide valuable structural information toward a comprehensive understanding of HS biosynthesis.

Acknowledgments—We thank Dr. Ashutosh Tripathy (University of North Carolina, Macromolecular Interaction Facility) for the assistance with isothermal titration calorimetry study, Dr. Joe Krahn for help in structure determination, Dr. Z. Jin of SER-CAT for collection of the data, and Drs. Jeffrey Boyington and Lee G. Pedersen as well as Andrea Moon for critical reading of the manuscript. Use of the Advanced Photon Source was supported by the United States Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract W-31-109-Eng-38.

REFERENCES

1. Esco, J. D., and Selleck, S. B. (2002) Annu. Rev. Biochem. 71, 435–471
2. Rosenberg, R. D., Showler, N. W., Liu, J., Schwartz, J. J., and Zhang, L. (1997) J. Clin. Invest. 99, 2062–2070
3. Liu, J., and Thorp, S. C. (2002) Med. Res. Rev. 22, 1–25
4. Lindahl, U., Kusche-Gullberg, M., and Kjellen, L. (1998) J. Biol. Chem. 273, 24979–24982
5. Koberan, B., Lech, M. Z., Beeler, D. L., Wu, Z. L., and Rosenberg, R. D. (2003) Nat. Biotechnol. 21, 1343–1346
6. Atha, D. H., Lormeau, J.-C., Petitou, M., Rosenberg, R. D., and Choy, J. (1985) Biochemistry 24, 6723–6729
7. Dewerchin, M., Hersul, J.-P., Wallays, G., Petitou, M., Schaeffer, P., Millet, L., Weitz, J. I., Moons, L., Collen, D., Carmeliet, P., and Herbert, J.-M. (2003) Circulation 108, 1120–1126
8. Kide, T., Oda, S., Takahashi, K., One, T., and Sakuragawa, N. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 289–293
9. van Boven, H. H., and Lane, D. A. (1997) Semin. Hematol. 34, 188–204
10. Boyer, C., Wolf, M., Vedrenne, J., Meyer, D., and Larrieu, M. J. (1986) Thromb. Haemostasis 56, 18–22
11. Weitz, J. I. (2003) J. Clin. Invest. 111, 952–954
12. Liu, J., Showler, N. W., Fransson, M. E., Edberg, J. M., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 57072–57078
13. Duncan, M. B., Chen, J., Krise, J. P., and Liu, J. (2004) Biochem. Biophys. Acta 1671, 34–43
14. HajMohammadi, S., Enjyoji, K., Princivalle, M., Christi, P., Lech, M., Beeler, D. L., Rayburn, H., Schwartz, J. J., Barzegar, S., de Agostini, A. I., Post, M. J., Rosenberg, R. D., and Showler, N. W. (2003) J. Clin. Invest. 111, 999–1009
15. Liu, J., and Rosenberg, R. D. (2002) in Handbook of Glycosyltransferases and Their Related Genes (Taniguchi, N., and Fukuda, M., eds) pp 475–483, Springer-Verlag, Tokyo
16. Xia, G., Chen, J., Tswai, V., Wu, L. J., Li, P., Malmström, A., Shukla, D., and Liu, J. (2002) J. Biol. Chem. 277, 37592–375919
17. Shukla, D., Liu, J., Blacklock, P., Showler, N. W., Bai, X., Esco, J. D., Cohen, G. H., Eisenberg, R. J., Rosenberg, R. D., and Spear, P. G. (1999) Cell 99, 13–22
18. Negishi, M., Pedersen, L. G., Petrochenko, E., Shvetsov, S., Greskovik, A., Kakuta, Y., and Pedersen, L. C. (2001) Arch. Biochem. Biophys. 390, 149–157
19. Grunwell, J. R., and Bertozzi, C. R. (2002) Biochemistry 41, 13117–13126
20. Kakuta, Y., Pedersen, L. G., Carter, C. W., Negishi, M., and Pedersen, L. C. (1997) Nat. Struct. Biol. 4, 904–908
21. Kakuta, Y., Suyoshi, T., Negishi, M., and Pedersen, L. C. (1999) J. Biol. Chem. 274, 10673–10676
22. Kakuta, Y., Petrochenko, E., Pedersen, L. C., and Negishi, M. (1998) J. Biol. Chem. 273, 2735–27350
23. Lee, K. A., Podia, H., Lee, Y. C., Negishi, M., Strott, C. A., and Pedersen, L. C. (2003) J. Biol. Chem. 278, 44503–44509
24. Pedersen, L. C., Petrochenko, E., Shvetsov, S., and Negishi, M. (2002) J. Biol. Chem. 277, 17928–17932
25. Showler, N. W., Liu, J., Fritze, L. M. S., Schwartz, J. J., Zhang, L., Logar, D., and Rosenberg, R. D. (1997) J. Biol. Chem. 272, 28008–28019
26. Bame, K. J., and Esco, J. D. (1989) J. Biol. Chem. 264, 8059–8065
27. Greskovik, A., and Minor, V. (1997) Methods Enzymol. 276, 307–326
28. Bailey, S. (1994) Acta Crystallogr. Sect. D 50, 760–763
29. Vagin, A., and Teplyakov, A. (1997) J. Appl. Crystallogr. 30, 1022–1025
30. Kwan, S. W., Adams, P. D., Clare, G. M., DeLano, W. L., Gros, P., Grzesi- Kanust, E., Wang, J. S., Kuszezus, J., Milles, P., Pann, N. S., Read, R. J., Rice, L. M., Simonsson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D 54, 905–923
31. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110–119
32. Matthews, B. W. (1968) J. Mol. Biol. 38, 491–497
33. Greskovik, A., and Minor, V. (1997) Methods Enzymol. 139, 473–497
34. Mattson, T. J., van der Stelt, P., van der Plas, M. J., and van der Veen, C. (2003) J. Biol. Chem. 278, 25008–25014
35. Myette, J. R., Shriver, Z., Liu, J., Venkataraman, G., Rosenberg, B., and Sassekharan, R. (2002) Biochem. Biophys. Res. Commun. 290, 1206–1213
36. Showler, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, N. A., and Rosenberg, R. D. (1999) J. Biol. Chem. 274, 5170–5184
37. Krasil, P. F. (1991) J. Appl. Crystallogr. 24, 946–950
38. Merriam, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505–524
39. Chen, J., Duncan, M. B., Carrick, K., Pope, M., and Liu, J. (2003) Glycobiology 13, 785–794

*The corresponding amino acid residue for Arg-67 of 3-OST-1 in 3-OST-2, 3-OST-3, and 3-OST-5 are Lys-113, Lys-136, and Arg-99, respectively. The corresponding amino acid residue for 3-OST-4 is not published.*